4R-Tau Targeting Therapy is a novel therapeutic approach specifically designed for Progressive Supranuclear Palsy (PSP) and other 4R-tauopathies. This therapy targets the selective reduction of the tau isoform containing four microtubule-binding repeats (4R-tau), which is the predominant form driving pathology in PSP.
PSP is characterized by the accumulation of hyperphosphorylated 4R-tau in neurons and glia, particularly in the basal ganglia, subthalamic nucleus, brainstem oculomotor nuclei, and cerebellar dentate nucleus. Unlike Alzheimer's disease where both 3R and 4R tau isoforms are present, PSP is a "pure 4R-tauopathy," meaning therapeutic strategies can be isoform-specific.
Key pathological features:
- 4R-tau filaments form neurofibrillary tangles in subcortical structures
- Neuronal loss in globus pallidus externa and interna
- Subthalamic nucleus degeneration
- Oculomotor nerve palsy due to midbrain involvement
- Falls due to axial rigidity and bradykinesia
This therapy employs multiple complementary mechanisms to achieve 4R-tau reduction:
- MAPT exon 10 splicing modulation — ASO or RNAi approaches to shift alternative splicing away from exon 10 inclusion, reducing 4R-tau production at the source
- 4R-tau degradation enhancers — Small molecules or biologics that enhance the clearance of existing 4R-tau aggregates via autophagy-lysosome or proteasome pathways
- Tau aggregation inhibitors — Compounds that specifically prevent 4R-tau monomer polymerization into oligomers and fibrils
- Conformational epitope antibodies — monoclonal antibodies that selectively recognize and neutralize 4R-tau species
| Dimension |
Score |
Rationale |
| Novelty |
9 |
First-in-class approach targeting isoform-specific mechanism in PSP |
| Mechanistic Rationale |
9 |
Strong genetic and biochemical evidence for 4R-tau as primary driver of PSP pathology |
| Root-Cause Coverage |
9 |
Addresses the fundamental isoform imbalance rather than downstream effects |
| Delivery Feasibility |
7 |
ASO delivery to brain feasible via intrathecal or convective delivery; AAV vectors under development |
| Safety Plausibility |
7 |
3R-tau preservation may reduce off-target effects; requires careful monitoring |
| Combinability |
8 |
Synergistic with neuroinflammation modulators, brainstem circuit support, and anti-oxidative stress approaches |
| Biomarker Availability |
8 |
CSF 4R-tau/3R-tau ratio available; PET tracers under development |
| De-risking Path |
7 |
Can leverage existing tau therapeutic development pathways; need 4R-specific biomarkers |
| Multi-disease Potential |
6 |
Primary indication PSP; applicable to CBD, AGD, and other 4R-tauopathies |
| Patient Impact |
9 |
Addresses fundamental cause of PSP; high unmet need in this rapidly progressive disorder |
Total Score: 79/100
| Disease |
Coverage Score |
Rationale |
| Alzheimer's Disease |
3 |
Mixed 3R/4R tauopathy; primary strategy targets 3R+4R |
| Parkinson's Disease |
2 |
Not primarily 4R-tau driven |
| ALS |
2 |
TDP-43 pathology predominant |
| FTD |
5 |
Some FTD cases have 4R-tau; depends on subtype |
| PSP |
10 |
Primary indication; strong mechanistic rationale |
| MSA |
3 |
Alpha-synuclein pathology predominant |
| Aging |
4 |
May have incidental tau pathology |
- Validate 4R-tau/3R-tau ratio modulation in iPSC-derived neurons from PSP patients
- Test ASO efficacy in tau transgenic models with 4R-tau overexpression
- Establish PK/PD relationship for brain delivery
- GLP toxicology in non-human primates
- Monitor for compensatory changes in 3R-tau expression
- Assess immune response to tau-targeting biologics
- Patient enrichment: Select PSP patients with elevated CSF 4R-tau
- Biomarker-driven dosing based on CSF 4R-tau/3R-tau ratio
- Clinical endpoints: PSP Rating Scale,falls frequency, vertical gaze palsy progression
- 3R-tau preservation: Careful dose-finding to avoid complete tau reduction
- Off-target effects: Use isoform-specific promoters and targeting sequences
- Immunogenicity: Humanized antibodies, minimized foreign protein motifs
4R-Tau Targeting Therapy is ideally suited for combination approaches:
- + Neuroinflammation modulation — Reduce microglial activation triggered by tau debris
- + Brainstem circuit support — Protect remaining neurons in critical circuits
- + Antioxidant therapy — Address oxidative stress in vulnerable populations
- + Physical therapy adjunct — Maximize functional benefit of neuron preservation
- MAPT H1 haplotype associated with increased PSP risk
- Mutations in MAPT exon 10 causing PSP-like phenotypes (splicing mutations)
- Tau gene duplications leading to 4R-tau overexpression
- Elevated 4R-tau in PSP brain tissue vs. age-matched controls
- 4R-tau specifically enriched in PSP neurofibrillary tangles
- Post-mortem studies show correlation between 4R-tau burden and clinical severity
- Transgenic mice with human 4R-tau show PSP-like pathology
- AAV-mediated 4R-tau overexpression in rodents producesNFT-like inclusions
- ASO-mediated exon 10 skipping reduces 4R-tau in preclinical models
- Complete IND-enabling studies for lead ASO candidate
- Establish CSF 4R-tau assay for patient stratification
- Initiate Phase 1 clinical trial in PSP patients
- Complete Phase 1 safety assessment
- Initiate biomarker-driven Phase 2 efficacy trial
- Explore AAV-based gene therapy approach
- Pivotal registration trial for PSP
- Expand to other 4R-tauopathies (CBD, AGD)
- Develop oral small-molecule option for chronic dosing
- Identify lead compound: Screen existing tau ASOs for 4R-tau specificity
- Engage clinical experts: Connect with PSP clinical centers for trial site development
- Biomarker development: Validate CSF 4R-tau/3R-tau ratio as patient enrichment biomarker
- Regulatory dialogue: Pre-IND meeting with FDA to discuss accelerated approval pathway
- Patient advocacy engagement: Partner with CurePSP and other patient organizations